The PARTNER II Trial: SAPIEN XT Transcatheter Aortic Valve
A New Alternative to Surgery for Patients
The PARTNER II Clinical Trial is designed to investigate the next generation transcatheter aortic valve, the Edwards SAPIEN XT, in both intermediate and high-surgical risk patients, as well as inoperable patients. Providence Valve Center has successfully enrolled more than 20 patients in PARTNER II this year.
Specific patients who are candidates for the trial include:
Learn more about the PARTNER II Clinical Trial
- Severe aortic stenosis
- Intermediate or high risk for traditional aortic valve surgery
- Society of Thoracic Surgeons (STS) predicted risk of mortality for surgery >4%
- Patients at higher surgical risk are candidates for referral, including those with advanced age, previous sternotomy or chest irradiation, porcelain (heavy calcification) of the ascending aorta, frailty or debility, and significant comorbidities such as cerebral or peripheral vascular disease or renal insufficiency.
from Edwards Lifesciences. For more information, please contact Angela Redd at 503-216-2170 or Heather Aiona at 503-216-2099.